Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in North Carolina: - Cone Health Cancer Center at Asheboro — Asheboro, North Carolina
- Cone Health MedCenter Asheboro — Asheboro, North Carolina
- AdventHealth Infusion Center Asheville — Asheville, North Carolina
- Cone Health Cancer Center at Alamance Regional — Burlington, North Carolina
- UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in North Carolina: - Duke Cancer Center Cary — Cary, North Carolina
- UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Novant Health Presbyterian Medical Center — Charlotte, North Carolina
- Novant Health Colon and Rectal Clinic — Clemmons, North Carolina
- Duke University Medical Center — Durham, North Carolina
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in North Carolina: - Cone Health MedCenter Asheboro — Asheboro, North Carolina
- Cone Health Cancer Center at Alamance Regional — Burlington, North Carolina
- Cone Health Cancer Center — Greensboro, North Carolina
- Cone Health Cancer Center at Drawbridge Parkway — Greensboro, North Carolina
- Annie Penn Memorial Hospital — Reidsville, North Carolina
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…
Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in North Carolina: - Research Site — Charlotte, North Carolina
- Research Site — Durham, North Carolina
- Research Site — Greensboro, North Carolina
- Research Site — Greenville, North Carolina
- Research Site — Pinehurst, North Carolina
Phase 3 Recruiting Academic/Other
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to der…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT06377852
Sites in North Carolina: - Levine Cancer Institute — Albemarle, North Carolina
- Levine Cancer Institute — Charlotte, North Carolina
- Levine Cancer Institute — Charlotte, North Carolina
- Levine Cancer Institute — Charlotte, North Carolina
- Levine Cancer Institute — Charlotte, North Carolina
Phase 3 Recruiting Industry
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Sites in North Carolina: - Duke Cancer Network — Durham, North Carolina
- Cone Health Cancer Center — Greensboro, North Carolina
Phase 3 Recruiting Industry
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in North Carolina: - Duke Women Cancer Care — Raleigh, North Carolina
Phase 3 Recruiting Industry
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312176
Sites in North Carolina: - Levine Cancer Institute ( Site 0014) — Charlotte, North Carolina
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in North Carolina: - Local Institution - 0276 — Durham, North Carolina
Phase 3 Recruiting Academic/Other
The main goal of this clinical trial is to test benefits of completing online pain coping skills training program in women who have been diagnosed with stage I-III breast cancer, who have completed their primary cancer treatment, who are t…
Sponsor: Northwestern University
NCT ID: NCT05703178
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in North Carolina: - Cone Health MedCenter Asheboro — Asheboro, North Carolina
- Cone Health Cancer Center at Alamance Regional — Burlington, North Carolina
- Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina
- Duke University Medical Center — Durham, North Carolina
- Southeastern Medical Oncology Center-Goldsboro — Goldsboro, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in North Carolina: - Regional Medical Oncology Center — Wilson, North Carolina
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in North Carolina: - UNC Hospitals, University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
Phase 2 Recruiting Academic/Other
This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The nam…
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04468061
Sites in North Carolina: - The University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
Sponsor: Apollo Therapeutics Ltd
NCT ID: NCT06399757
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
- Carolina BioOncology Institute — Huntersville, North Carolina
Phase 2 Recruiting Academic/Other
This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \& Heel cancer exercise program (MEM+EX) in addressing cancer-re…
Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT06727773
Sites in North Carolina: - Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill — Chapel Hill, North Carolina
Phase 2 Recruiting Academic/Other
The aim of this prospective study is to investigate quality of life and oncologic outcomes in low-risk elderly breast cancer patients randomized to adjuvant therapy with accelerated partial breast irradiation (APBI) alone or endocrine ther…
Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT05472792
Sites in North Carolina: - University of North Carolina — Chapel Hill, North Carolina
Phase 2 Recruiting Academic/Other
This is a multicenter, multi-arm, biomarker-stratified trial designed to evaluate biomarker-directed therapies in patients with estrogen receptor-positive/hormone receptor-negative (ER+/HR-) and triple-negative (TN) metastatic breast cance…
Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT07340541
Sites in North Carolina: - Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill — Chapel Hill, North Carolina
Phase 2 Recruiting Academic/Other
This is a 4-arm, single-center study involving 40 participants. Ten healthy volunteers will be enrolled for system imaging optimization, and thirty (30) patients with previously identified lesions in the breast, liver, or kidney-based on p…
Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT07225114
Sites in North Carolina: - The University of North Carolina — Chapel Hill, North Carolina
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
Phase 1 Recruiting Industry
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is …
Sponsor: Eli Lilly and Company
NCT ID: NCT07213791
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 1 Recruiting Industry
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapi…
Sponsor: Incyte Corporation
NCT ID: NCT05238922
Sites in North Carolina: - Carolina Bio-Oncology Institute, Pllc — Huntersville, North Carolina
Phase 1 Recruiting Industry
This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment …
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT05508906
Sites in North Carolina: - Atrium Health Levine Cancer Institute — Charlotte, North Carolina
Phase 1 Recruiting Industry
This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants wi…
Sponsor: BeOne Medicines
NCT ID: NCT06120283
Sites in North Carolina: - Duke Cancer Center — Durham, North Carolina
Phase 1 Recruiting Industry
The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expr…
Sponsor: EMD Serono Research & Development Institute, Inc.
NCT ID: NCT07360314
Sites in North Carolina: - Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center — Huntersville, North Carolina